Cargando…
Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma
Chemotherapy is considered “state of the art” for the treatment of poorly differentiated neuroendocrine neoplasms. Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic neuroendocrine neoplasms. We report the case of a patient with a...
Autores principales: | Ribeiro, Maria João Marques, Alonso, Teresa, Gajate, Pablo, Molina, Javier, Barquin, Arantzazu, Perna, Cristian, Grande, Enrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
São Paulo, SP: Universidade de São Paulo, Hospital Universitário
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828287/ https://www.ncbi.nlm.nih.gov/pubmed/29515980 http://dx.doi.org/10.4322/acr.2018.005 |
Ejemplares similares
-
Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017) -
Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
por: Grande, Enrique, et al.
Publicado: (2017) -
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2015) -
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
por: Vida Navas, Elena María, et al.
Publicado: (2021) -
Management dilemma of a recurrent huge fibrosarcoma in a 25-year-old African: a case report
por: Adigun, Ismaila A, et al.
Publicado: (2009)